http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013138180-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
filingDate 2012-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2015-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2013138180-A
titleOfInvention METHODS FOR TREATMENT OF MACULAR Edema WITH THE USE OF ANTI-DRAINAGE MEDICINES
abstract 1. A method of treating macular edema in a patient, comprising determining whether the patient has been diagnosed with macular edema or if the patient experiences symptoms of macular edema within a predetermined period of time, or determining whether the patient has a significant deterioration in visual acuity, or determining both of them; and if the patient experiences symptoms of macular edema for a predetermined period of time or, optionally, has a significant deterioration in visual acuity, the administration of a therapeutically effective amount of decongestant drug (POL) to the patient. 2. A method of treating macular edema in a patient, comprising determining whether the patient experiences symptoms of macular edema for a predetermined period of time; optionally, determining whether the patient has a significant deterioration in visual acuity; and if the patient does not experience symptoms of macular edema for a predetermined period of time or, optionally, does not have a significant deterioration in visual acuity, treating the patient with other types of therapy other than decongestant drug (POL). 3. A method for treating macular edema in a patient, comprising determining whether the patient has been diagnosed with macular edema within a predetermined period of time, or determining whether the patient has a significant deterioration in visual acuity, or determining both of them; and if the patient is diagnosed with macular edema within a predetermined period of time or, optionally, the patient has a significant deterioration in visual acuity, the introduction of a therapeutically effective
priorityDate 2011-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5755
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64929
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311051
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222786
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527393
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581125
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91488
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311101
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6603935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70695616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3715
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502241
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426359946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441335
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506776
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31307
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419129972
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535732
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505112
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420709326
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414862877
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502930
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5754
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533798
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9642
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441336
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559541
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21700
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8121
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID40000
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419479543
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419584633
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419477255
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535682
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20469
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6436
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6215
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506586
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID151075
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415789973
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492800
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504256
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5461123
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID82153
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581812
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54675783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582418
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6919
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7904
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506142
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501808
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497181
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546247
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533988

Total number of triples: 75.